Asston Pharmaceuticals Limited has officially commenced commercial production at its Unit II facility on January 21, 2026. The company informed BSE Limited about this significant operational milestone through a regulatory filing under SEBI listing obligations.

Facility Details and Location

The new manufacturing unit is strategically located at Plot no W 18-A, MIDC, Additional Ambernath, Anand Nagar Industrial area, District Thane, Mumbai, Maharashtra 421501. The facility has been designed to manufacture both pharmaceuticals and nutraceuticals products, expanding the company's production capabilities.

Regulatory Compliance and Timeline

The commencement follows the company's scheduled plan and is in continuation of their earlier communication dated November 14, 2025, regarding capacity addition. The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance.

Company Background

Asston Pharmaceuticals Limited, formerly known as Asston Pharmaceuticals Private Limited, operates under CIN U24304MH2019PLC324187. The company is listed on BSE with code 544445 and ISIN INE0SJX01015. Their registered office is located at 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra.

Strategic Significance

The operationalization of Unit II represents a key expansion milestone for the pharmaceutical company. By adding manufacturing capacity for both pharmaceuticals and nutraceuticals products, the company is positioning itself to serve growing market demand in these therapeutic segments. The facility's location in Maharashtra's established industrial corridor provides strategic advantages for distribution and logistics.

The announcement was signed by Rishi Upadhaya, Company Secretary and Compliance Officer, confirming the company's commitment to transparent communication with stakeholders and regulatory authorities.

Asston Pharmaceuticals Limited has announced that its board of directors approved a car loan facility from HDFC Bank Limited during a meeting held on January 5, 2026. The decision was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting was conducted at the company's registered office from 3:00 PM to 4:30 PM on January 5, 2026. Company Secretary and Compliance Officer Rishi Upadhaya signed the disclosure document, ensuring proper regulatory compliance for the listed pharmaceutical company.

Loan Facility Specifications

The approved car loan facility includes specific terms and security arrangements as outlined by the board:

Security and Terms Structure

The loan facility will be secured against the moveable assets to be purchased with the loan proceeds, specifically the vehicles themselves. This self-securing arrangement provides HDFC Bank with direct collateral tied to the loan's intended use. The specific tenure and interest rate details will be determined through the formal loan agreement to be executed between Asston Pharmaceuticals Limited and HDFC Bank Limited.

Regulatory Compliance

The company has fulfilled its disclosure obligations under SEBI regulations by promptly informing BSE Limited about this material development. The announcement was made to the BSE Listing and Compliance Department, referencing the company's ISIN code INE0SJX01015 and BSE code 544445. This disclosure ensures transparency for shareholders and market participants regarding the company's financing decisions and capital allocation strategies.